GB Sciences, Inc. (OTCQB:GBLX)
GB Sciences, Inc. (OTCQB:GBLX) is a phytomedical research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures for a variety of conditions. GB Sciences’ novel drug discovery platform has yielded 5 issued US and 3 issued international patents, as well as 10 US and 35 international patent-pending applications. In our drug development pipeline, we have four preclinical stage programs, and our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial.
GB Sciences presenting at SACHS April 29, 2021
Most Recent Investor Presentation
GB Sciences’ Drug Development Programs
Letter to Shareholder's
GBLX Stock Price
The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes